← Back to Search

Other

INZ-701 for Pseudoxanthoma Elasticum and Arterial Calcification

Phase 2
Recruiting
Research Sponsored by Inozyme Pharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 years (long term safety assessment)
Awards & highlights

Summary

This trial aims to evaluate the safety of a drug called INZ-701 in patients with specific genetic conditions who have previously taken the drug in another study and wish to continue treatment.

Who is the study for?
The ADAPT study is for males and females over 1 year old with ENPP1 or ABCC6 Deficiency who have previously taken INZ-701 in a clinical trial. They must be able to complete the study, provide consent (or assent if under 18), and use effective contraception.
What is being tested?
This trial tests the long-term safety of INZ-701, a potential treatment for conditions like Pseudoxanthoma Elasticum and various forms of Hypophosphatemic Rickets associated with ENPP1 or ABCC6 genetic mutations.
What are the potential side effects?
Specific side effects are not listed here, but this study focuses on understanding the long-term safety profile of INZ-701 by monitoring any adverse reactions in participants continuing its use from previous trials.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 years (long term safety assessment)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 years (long term safety assessment) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of Anti-Drug Antibodies (ADA)
Number of Treatment Emergent Adverse Events (TEAEs)
Secondary study objectives
Maximum Plasma Concentration (Cmax) of INZ-701
Mean Change from Baseline in Plasma PPi Concentration
Time to maximum serum concentration (Tmax)

Trial Design

1Treatment groups
Experimental Treatment
Group I: INZ-701Experimental Treatment1 Intervention
INZ-701 will be administered by subcutaneous injection on a once-weekly basis as follows: * Study participants from 1 year to \<13 years of age will receive a dose of 2.4 mg/kg * Study participants ≥13 years will either receive a 1.8 mg/kg dose or a 150 mg flat dose of INZ-701

Find a Location

Who is running the clinical trial?

Inozyme PharmaLead Sponsor
8 Previous Clinical Trials
1,151 Total Patients Enrolled
4 Trials studying Pseudoxanthoma Elasticum
1,056 Patients Enrolled for Pseudoxanthoma Elasticum
Kurt Gunter, MDStudy DirectorInozyme Pharma, Inc.
8 Previous Clinical Trials
1,120 Total Patients Enrolled
2 Trials studying Pseudoxanthoma Elasticum
1,010 Patients Enrolled for Pseudoxanthoma Elasticum
~133 spots leftby Nov 2030
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top